KU675, a concomitant heat-shock protein inhibitor of Hsp90 and Hsc70 that manifests isoform selectivity for Hsp90α in prostate cancer cells

Molecular Pharmacology

Volumn 88, Issue 1, 2015, Pages 121-130

  Liu, Weiya ^a   Vielhauer, George A ^a   Holzbeierlein, Jeffrey M ^a   Zhao, Huiping ^b   Ghosh, Suman ^b   Brown, Douglas ^a   Lee, Eugene ^a   Blagg, Brian S J ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK PROTEIN 90 BETA; HEAT SHOCK PROTEIN 90 INHIBITOR; KU 675; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; COUMARIN DERIVATIVE; HEAT SHOCK COGNATE PROTEIN 70; HSP90ALPHA PROTEIN, HUMAN; KU675 COMPOUND; NOVOBIOCIN; PROTEIN BINDING;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CELL DEATH; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; MALE; METABOLISM; PROSTATE TUMOR; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSC70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; NOVOBIOCIN; PHENYLUREA COMPOUNDS; PROSTATIC NEOPLASMS; PROTEIN BINDING;

EID: 84940185964     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.097303     Document Type: Article

References (47)

1. An WG, Schulte TW, and Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355-360.
2. Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, and Blagg BS (2006) High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett 16:3005-3008.
3. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, and Harper W (2004) High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10:6572-6578.
4. Basso AD, Solit DB, Munster PN, and Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-1166.
5. Blagosklonny MV, Toretsky J, and Neckers L (1995) Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933-939.
6. Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, and Blagg BS (2008) Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem 73:2130-2137.
7. Chen B, Piel WH, Gui L, Bruford E, and Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86:627-637.
8. Chen B, Zhong D, and Monteiro A (2006) Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms. BMC Genomics 7:156-175.
9. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, and Gleave ME et al. (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247-4254.
10. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, and Neckers L (2003) 17AAG: low target binding affinity and potent cell activity: finding an explanation. Mol Cancer Ther 2:123-129.
11. Csermely P, Schnaider T, Soti C, Prohászka Z, and Nardai G (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications: a comprehensive review. Pharmacol Ther 79:129-168.
12. Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, and Rajewski RA et al. (2011) Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 11:468-484.
13. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
14. Holzbeierlein JM, Windsperger A, and Vielhauer G (2010) Hsp90: a drug target? Curr Oncol Rep 12:95-101.
15. Huggins C (1952) Endocrine factors in cancer. J Urol 68:875-884.
16. Huggins C and Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9-12.
17. Isaacs JS, Xu W, and Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213-217.
18. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, and Kaplan E et al. (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540.
19. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, and Berman DM (2007) Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 67:9199-9206.
20. Kusuma BR, Khandelwal A, Gu W, Brown D, Liu W, Vielhauer G, Holzbeierlein J, and Blagg BS (2014) Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorg Med Chem 22:1441-1449.
21. Lassi K and Dawson NA (2010) Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 22:263-267.
22. Marcu MG, Chadli A, Bouhouche I, Catelli M, and Neckers LM (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem275:37181-37186.
23. Martin CJ, Gaisser S, Challis IR, Carletti I, Wilkinson B, Gregory M, Prodromou C, Roe SM, Pearl LH, and Boyd SM et al. (2008) Molecular characterization of macbecin as an Hsp90 inhibitor. J Med Chem 51:2853-2857.
24. Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, and Holzbeierlein JM (2010) Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 70:27-36.
25. Mohler JL (2008) A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 22:357-372.
26. Ohba S, Hirose Y, Yoshida K, Yazaki T, and Kawase T (2010) Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg 112:33-42.
27. Peterson LB, Eskew JD, Vielhauer GA, and Blagg BS (2012) The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Mol Pharm 9:1841-1846.
28. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, and Kohli M et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520.
29. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, and Fidler IJ (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627-1636.
30. Powers MV and Workman P (2007) Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581:3758-3769.
31. Qin H, Hu J, Hua Y, Challa SV, Cross TA, and Gao FP (2008) Construction of a series of vectors for high throughput cloning and expression screening of membrane proteins from Mycobacterium tuberculosis. BMC Biotechnol 8:51-59.
32. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, and Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260-266.
33. Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, and Holzbeierlein JM et al. (2013) Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol 11:478-488.
34. Sato S, Fujita N, and Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832-10837.
35. Schulte TW, Blagosklonny MV, Ingui C, and Neckers L (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-24588.
36. Schulte TW and Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273-279.
37. Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, and Matts RL et al. (2009) KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 76:1314-1322.
38. Siegel R, Ward E, Brawley O, and Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236.
39. Sreedhar AS, Kalmár E, Csermely P, and Shen YF (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562:11-15.
40. Stühmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, Müller S, Schoepfer J, Garcia-Echeverria C, Quadt C, and Jensen MR et al. (2009) Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800. Br J Haematol 147:319-327.
41. Suda A, Kawasaki K, Komiyama S, Isshiki Y, Yoon DO, Kim SJ, Na YJ, Hasegawa K, Fukami TA, and Sato S et al. (2014) Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors. Bioorg Med Chem 22:892-905.
42. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, and Turesson I et al.; TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl JMed351:1502-1512.
43. Thulasiraman V and Matts RL (1996) Effect of geldanamycin on the kinetics of chaperone-mediated renaturation of firefly luciferase in rabbit reticulocyte lysate. Biochemistry 35:13443-13450.
44. Thulasiraman V and Matts RL (1998) Luciferase renaturation assays of chaperones and chaperone antagonists. Methods Mol Biol 102:129-141.
45. Whitesell L and Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-772.
46. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, and Neckers L (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. JBiolChem276:3702-3708.
47. Zhang H and Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl) 82:488-499.